This Week’s CGT News: Eli Lilly’s Verve takeover, and more
June 24, 2025
Our latest news roundup reports on Eli Lilly’s Verve takeover, novel CRISPR delivery research, a growing interest in CD5-based immunotherapy, and more
3 min read
False
Advertisement
Advanced Medicine
Gene Therapy Meets Nanotechnology
By Stephanie Vine
June 24, 2025
Researchers explore how ocular gene delivery strategies for diabetic retinopathy could be improved using nanotechnology.
3 min read
Using Machine Learning to Improve Gene Therapy Design
By Stephanie Vine
June 11, 2025
Stanford University researchers explore how zinc fingers can enhance gene therapy.
2 min read
Preparing National Strategies for CAR T: The Latest IQVIA Report
By Rob Coker
June 5, 2025
The IQVIA Institute’s latest report evaluates how well seven countries are prepared to support the complex infrastructure required for CAR T therapies.
5 min read
This Week’s CGT News: Smart Cell Therapy Facility for Japan
June 4, 2025
Our latest news roundup reports on a cell therapy facility expansion in Princeton, a magnet to capture T cells, and more.
5 min read
Gene Therapies for Newborns
By Stephanie Vine
June 4, 2025
Work from the lab of Luigi Naldini identifies postnatal window for in vivo gene editing, without the need for conditioning or transplantation
2 min read
Clinical Hold for Rocket Pharmaceuticals’ Gene Therapy
By Stephanie Vine
June 2, 2025
Patient fatality reported in clinical trial for investigational gene therapy for Danon disease
2 min read
This Week’s CGT News: The Next Generation of AAVs
May 29, 2025
Our latest news roundup reports on a gene therapy for Duchenne muscular dystrophy that can be re-dosed, a free toolkit for gene delivery and more
5 min read
$400,000 Prize Honors Pioneers of CAR T-Cell Therapy
By Stephanie Vine
May 28, 2025
“The development of CAR T-cell technology is a defining moment in the history of biomedicine – one of the all-time amazing transformative breakthroughs.”
3 min read
Exploring Placenta-Derived Stem Cell Therapy
May 28, 2025
Researchers conduct small phase I study on the potential of placenta-derived stem cell therapy to treat a serious form of MS with limited therapeutic options
2 min read
